Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $126.4 million.

  • Capricor Therapeutics' Liabilities and Shareholders Equity rose 36.03% to $126.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $584.3 million, marking a year-over-year increase of 144.04%. This contributed to the annual value of $170.5 million for FY2024, which is 190.26% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Liabilities and Shareholders Equity of $126.4 million as of Q3 2025, which was down 5.34% from $133.6 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Liabilities and Shareholders Equity registered a high of $170.5 million during Q4 2024, and its lowest value of $37.2 million during Q3 2023.
  • For the 3-year period, Capricor Therapeutics' Liabilities and Shareholders Equity averaged around $87.3 million, with its median value being $58.7 million (2023).
  • As far as peak fluctuations go, Capricor Therapeutics' Liabilities and Shareholders Equity slumped by 31.11% in 2023, and later spiked by 248.95% in 2025.
  • Capricor Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $41.3 million in 2021, then grew by 21.21% to $50.1 million in 2022, then increased by 17.25% to $58.7 million in 2023, then surged by 190.26% to $170.5 million in 2024, then surged by 36.03% to $126.4 million in 2025.
  • Its last three reported values are $126.4 million in Q3 2025, $133.6 million for Q2 2025, and $153.8 million during Q1 2025.